| Bai 201522) | herpes zosterW:60(38/22) 49.17±11.34 | 4 w | LXD 100 ㎖ bid po + control (30) | Gabapentin capsule tid po + Acyclovir 0.3 g bid po (30) | 1.Simplified McGill pain score2.Oswestry disability index3.Hamilton anxiety scale score4.Hamilton depression scale score5.Th17 cell concentration | 1.I:19.5±3.2C:35.7±2.7(P<0.05)2.I:13.6±2.1C:21.7±2.9(P<0.05)3.I:13.70±3.82C:23.24±4.49(P<0.05)4.I:13.68±3.77C:31.23±5.16(P<0.05)5.The expression of Th17 cells in the observation group was significantly lower than that in the control group. | NR |
| Chen 202523) | herpes zosterI:35(23/12)54.42±2.33C:35(21/14)54.19±2.26 | 4 w | LXD 150 ㎖ tid po + control (35) | Acyclovir 0.4 g qd po (35)acetaminophen 500 ㎎ bid po PRN dihydrocodeine tartrate 10 ㎎ bid po PRNCompound lidocaine cream bid topically(for patients without skin lesions or experiencing pain after skin lesions have healed) | 1.The immune function index levels1-1.CD3+1-2CD4+1-3.CD8+1-4.CD4+/CD8+2.Traditional Chinese medicine syndrome score3.Pain score4.Symptom improvement time4-1.Time to blister cessation4-2.Time to scab formation4-3.Time to healing4-4.Time to pain relief5.Adverse reactions | 1-1.I:68.43±4.12C:57.14±3.28(P<0.05)1-2.I:49.03±3.58C:44.13±3.19(P<0.05)1-3.I:23.97±0.86C:28.16±1.14(P<0.05)1-4.I:1.93±0.55C:1.38±0.41(P<0.05)2.I:0.73±0.11C:1.59±0.14(P<0.05)3.I:3.12±0.36C:4.85±0.72(P<0.05)4-1.I:2.47±0.34C:3.85±0.43(P<0.05)4-2.I:6.12±1.01C:8.08±1.46(P<0.05) 4-3.I:10.37±0.88C:14.19±1.52(P<0.05) 4-4.I:17.12±0.79C:20.61±1.08(P<0.05) 5.I:5/35(14.29)C:3/35(8.57)(P>0.05) | I: headache(2)nausea(2) diarrhea(1)C:headache(1)nausea(2) |
| Sun 202524) | herpes zosterI:42(19/23)49.21±7.56C:42(18/24)50.02±8.75 | 4 w | LXD 200 ㎖ tid po + control (42) | Ganciclovir injection 5 ㎎/㎏ qd (42) | 1.Total effective rate2.Pain degree2-1.T3(3 weeks after treatment)2-2.T4(4 weeks after treatment)3.Serum pain mediators3-1.SP3-2.PGE24.Serum inflammatory factors4-1.TNF-α4-2.IL-65.Adverse reactions | 1.I:41/42(97.62) C:30/42(71.42)(P<0.05)2-1.I:2.41±1.22C:3.85±0.59(P<0.05)2-2.I:1.37±0.31C:2.65±1.57(P<0.05)3-1.I:46.65±6.20C:62.11±5.31(P<0.05)3-2.I:53.75±15.23C:72.31±11.26(P<0.05)4-1.I:10.64±1.25C:16.34±2.64(P<0.05)4-2.I:127.19±18.59C:186.34±11.58(P<0.05)5.I:6/42(14.29)C:8/42(19.05)(P>0.05) | I: nausea and vomiting(1) fatigue(2) somnolence(3)C:nausea and vomiting(2)fatigue(2) somnolence(4) |
| Ying 201225) | herpes zosterI:36(19/17) 49.65C:36(21/15) 37.78 | 1 w | LXD 100 ㎖ qd po + control (36) | Valacyclovir 0.3 g bid po (36) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Time to off scab2-4.Time to pain relief2-5.Time to healing3.VAS pain score4.Postherpetic neuralgia5.Adverse reactions | 1.I:29/36(80.6) C:23/36(63.9)(P<0.05)2-1.I:3.24±0.96C:5.21±1.10(P<0.05)2-2.I:6.52±1.14C:7.98±1.48(P<0.05)2-3.I:11.17±3.78C:14.08±2.26(P<0.05)2-4.I:4.28±0.86C:6.72±1.12(P<0.05)2-5.I:10.52±2.20C:14.54±3.94(P<0.05)3.I:2.43±1.23C:3.64±1.26(P<0.05)4.I:1/36(2.8)C:5/36(13.9)(P<0.05)5.I:13/36(36.1)C:13/36(36.1)(P>0.05) | I: drowsiness(4) gastrointestinal reactions(9)C:drowsiness(6)gastrointestinalreactions(7) |
| Yan 202326) | herpes zosterI:40(17/23) 46.27±3.16C:40(22/18) 46.44±3.23 | 10 d | LXD 150 ㎖ bid po + control (40) | Acyclovir injection 0.25 g bid IV + Ibuprofen-codeine sustained-release tablets 2-4 tablets every 12 hrs + Vit B12 injection 0.25 ㎎ qd IM + Transfer factor injection 3 ㎎ qod IM (40) | 1.CD4+2.CD8+3.IgM4.ICAM-15.CXCL106.NF-kB7.NLRP38.SP9.CGRP10.6-keto-PGE1α11.NRS for pain12.Symptom improvement time12-1.Time to blister cessation-2.Time to scab formation12-3.Time to off scab13.Total effective rate | 1.I:17.11±2.09C:14.14±1.65(P<0.05)2.I:11.05±1.01C:11.84±1.39(P<0.05)3.I:2.17±0.41C:1.91±0.35(P<0.05)4.I:0.81±0.22C:1.12±0.31(P<0.05)5.I:65.61±9.18C:81.93±11.26(P<0.05)6.I:2.16±0.44C:3.31±0.63(P<0.05)7.I:1.05±0.34C:1.46±0.48(P<0.05)8.I:528.14±25.14C:576.61±30.52(P<0.05)9.I:323.58±27.62C:304.76±25.81(P<0.05)10.I:34.14±5.14C:41.61±7.52(P<0.05)11.I:1.12±0.33C:3.21±0.56(P<0.05)12-1.I:3.11±0.71C:5.49±1.08(P<0.05)12-2.I:5.45±1.02C:7.41±1.53(P<0.05)12-3.I:12.05±1.18C:14.51±1.31(P<0.05)13.I:40/40(100)C:34/40(85)(P<0.05) | NR |
| Wang 201227) | herpes zosterI:89(48/41) 49.6C:89(46/43) 49.4 | 1 w | LXD po + control (89) | Famciclovir 0.25 g every 8 hrs (89) | 1.Total effective rate(Complete rehabilitation rate)2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Time to pain relief2-4.Time to healing3.Postherpetic neuralgia | 1.I:76/89(85.4)C:57/89(64)(P<0.05)2-1.I:2.74±0.76C:3.98±1.03(P<0.05)2-2.I:6.26±0.94C:8.38±1.22(P<0.05)2-3.I:4.27±9.39C:6.35±1.20(P<0.05)2-4.I:9.06±0.82C:14.90±4.59(P<0.05)3.I:2/89(2.2)C:9/89(10.1)(P<0.05) | nausea (a few cases) |
| Cao 202228) | herpes zosterI:60(34/26) 54.4±10.2C:60(35/25) 54.2±10.5 | 1 w | LXD 200 ㎖ bid po + control (60) | Valacyclovir hydrochloride tablets 300 ㎎ bid po + Mecobalamin tablets 0.5 ㎎ tid po + diclofenac sodium sustained-release capsules 0.1 g bid po + acyclovir cream(for herpes lesions on unbroken skin) bid apply topically or Kangfuxin liquid(for ruptured blisters) bid apply topically (60) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to pain relief2-3.Time to scab formation3.Postherpetic neuralgia4.Adverse reactions | 1.I:54/60(90)C:45/60(75)(P<0.05)2-1.I:2.86±0.72C:4.62±1.28(P<0.05)2-2.I:3.88±1.18C:5.62±1.26(P<0.05)2-3.I:5.62±1.22C:6.72±1.18(P<0.05)3.I:1/60(1.7)C:8/60(13.3)(P<0.05)4.I:2/60(3.33)C:2/60(3.33)(P>0.05) | I: nausea(1) diarrhea(1)C:stomach discomfort(1)nausea(1) |
| Yu 201929) | herpes zosterI:42(21/21) 45.47C:42(20/22) 46.57 | 4 w | LXD 70 ㎖ bid po + control (42) | Valaciclovir 0.3 g bid po (42) | 1.Symptom improvement time1-1.Time to pain relief1-2.Time to blister cessation1-3.Time to scab formation1-4.Time to off scab2.Adverse reactions | 1-1.I:4.30±1.89C:5.25±4.02(P<0.05)1-2.I:3.74±2.16C:6.83±2.24(P<0.05)1-3.I:6.47±1.89C:8.27±2.54(P<0.05)1-4.I:9.36±2.63C:11.42±3.93(P<0.05)2.I:2/42(4.15)C:6/42(12.8)(P>0.05) | I: headache(1)stomach discomfort(1)C:headache(2)fever(1)stomach discomfort(3) |
| Yu 202030) | herpes zosterI:40(22/18) 46.5±9.3C:40(23/17) 45.8±9.1 | 10 d | LXD bid po + control (40) | Valaciclovir hydrochloride tablets 0.3 g bid po (40) | 1.Total effective rate2.Adverse reactions | 1.I:38/40(95)C:31/40(77.5)(P<0.05)2.I:3/40(7.5)C:2/40(5)(P>0.05) | I: stomachachenausea(3)C:stomachachenausea(2) |
| Dan 200331) | herpes zosterW:42(25/17)31.4I:24C:18 | 2 w | LXD bid po + control (24) | Poly I:C 2 ㎎ IM qod + Moroxydine 0.2 g tid po + Ribavirin 0.6-0.8 g + glucose 500 ㎖ IV + Acyclovir ointment tid apply topically + Acyclovir eye drops(In cases of keratitis) + atropine (In cases of keratitis iridocyclitis) (18) | 1.Total effective rate2.Time to healing | 1.I:23/24(96)C:10/18(56)(P<0.01)2.I:8.4C:12.5(P<0.01) | NR |
| Qiao 201932) | herpes zosterI:35(17/18) 48.86±9.12C:35(16/19) 48.45±9.42 | 10 d | LXD 200 ㎖ bid po + control (35) | Valacyclovir hydrochloride tablets 0.3 g bid po + Calamine lotion bid apply topically (35) | 1.Total effective rate(calculation method unavailable)2.Time for subjective symptoms to disappear | 1.I:33/35(94.29)C:26/35(74.29)(P<0.05).I:3.41±0.86C:5.86±1.12(P<0.05) | NR |
| Tian 201333) | herpes zosterI:70(41/29) 51C:70(37/33) 50.5 | 1-2 w | LXD bid po + control (70) | Acyclovir injection 250 ㎎ + N/S 250 ㎖ bid IV + Acyclovir ointment every 2 hrs apply topically + Diclofenac sodium sustained-release capsules(for patients with severe localized pain) (70) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Skin lesion healing time2-4.Time to pain relief | 1.I:70/70(100)C:62/70(88.6)(P<0.05)2-1.I:2.11±0.92C:4.27±1.10(P<0.05)2-2.I:4.39±1.23C:5.99±1.36(P<0.05)2-3.I:8.71±2.41C:11.02±2.52(P<0.05)2-4.I:5.01±1.58C:7.12±1.27(P<0.05) | NR |
| Gu 200534) | herpes zosterI:52(29/23)64.3C:30(18/12)60.7 | 10 d | LXD bid po + control (52) | Acyclovir 0.2 g 5 times daily po + Vit B12 1 ㎎ qd IM (30) | 1.Total effective rate | 1.I:51/52(98.1) C:28/30(93.3)(P<0.05) | NR |
| Shen 201935) | herpes zosterI:26(14/12)63.85±8.91C:25(13/12)64.28±9.03 | 1-2 w | LXD bid po + control (26) | Ganciclovir injection 500 ㎎ qd IV (25) | 1. Pain VAS1-1.3days after treatment1-2.7days after treatment1-3.14days after treatment2.Sleep quality2-1.After treatment2-2.2weeks after treatment3.Total effective rate | 1-1.I: 5.20±1.07C:6.59±1.02(P<0.05)1-2.I:3.26±0.82C:5.21±0.89(P<0.05)1-3.I:2.31±0.37C:3.87±0.42(P<0.05)2-1.I:10.25±1.72C:12.64±1.28(P<0.05)2-2.I:7.62±1.04C:9.62±1.33(P<0.05)3.I:24/26(92.31)C:17/25(68)(P<0.05) | NR |
| Wen 201436) | herpes zosterI:30(5/25)62.1C:30(10/20)65 | 1 w | LXD po + control (30) | Ribavirin injection 1 g qd IV + Transfer factor injection 3 ㎎ qod + Acyclovir 0.4 g tid po + Vit C tablets 50 ㎎ tid po + Calamine lotion apply topically (30) | 1.Total effective rate | 1.I:28/30(93.3) C:20/30(66.7)(P<0.05) | NR |
| Lu 201537) | herpes zosterI:33(16/17)56.4±6.8C:32(16/16)55.3±7.2 | 1 w | LXD bid po + control (33) | Acyclovir extended-release tablets 1.6 g tid po (32) | 1.Total effective rate2.Adverse reactions | 1.I:32/33(96.97) C:18/32(56.25)(P<0.05)2.I:1/33(3.03)C:1/32(3.13)(P>0.05) | Not specifically stated |
| Dong 200038) | herpes zosterI:40(30/10)41±10C:40(28/12)40.3±9 | NR | LXD qd po + control (40) | Poly I:C 2 ㎖ qod IM + Vit B1 10 ㎎ qd IM + Vit B12 50 μg qd IM (40) | 1.Total effective rate | 1.I:40/40(100)C:35/40(87.5)(P<0.01) | NR |
| Sun 201439) | herpes zosterI:18(10/8)45C:16(9/7)46 | 1-4 w | LXD 200 ㎖ bid po + control (18) | Ribavirin 0.3 g tid po + Vit B1 10 ㎎ tid po + Vit B12 25 μg tid po (16) | 1.Total effective rate | 1.I:16/18(89) C:11/16(68.8)(P<0.05) | NR |
| Zhang 201840) | herpes zosterI:75(15/60)64.8±3.7C:75(13/62)64.5±3.5 | 20 d | LXD 200 ㎖ bid po + control (75) | Valacyclovir hydrochloride capsules 0.3 g bid po + Mecobalamin capsules 1 g tid po + Acyclovir cream 4-6 times daily apply topically (75) | 1.Symptom improvement time1-1.Time to blister cessation1-2.Time to scab formation1-3.Time to off scab1-4.Time to pain relief2.Clinical symptom score2-1.Pain VAS2-2.Erythema2-3.Blister2-4.Degree of pain in skin lesions3.Biochemical marker3-1.CGRP3-2.5-HT3-3.ICAM-14.Total effective rate | 1-1.I:3.89±1.32C:5.63±1.44(P<0.05)1-2.I:6.23±1.78C:8.46±2.51(P<0.05)1-3.I:10.11±3.45C:14.67±4.67(P<0.05)1-4.I:3.11±1.23C:4.78±1.45(P<0.05)2-1.I:2.01±0.41C:2.77±0.56(P<0.05)2-2.I:0.72±0.34C:1.11±0.45(P<0.05)2-3.I:1.43±0.41C:2.16±0.56(P<0.05)2-4.I:0.68±0.34C:1.23±0.51(P<0.05)3-1.I:54.44±23.44C:100.45±31.23(P<0.05)3-2.I:41.44±18.45C:96.88±44.52(P<0.05)3-3.I:32.45±7.66C:84.56±13.45(P<0.05)4.I:70/75(93.33)C:62/75(82.67)(P<0.05) | NR |
| Zhu 201341) | herpes zosterI:36(19/17)39.4±5.6C:34(18/16)40.1±5.9 | 1 w | LXD bid po + control (36) | Ganciclovir 0.25 g + N/S 250 ㎖ qd IV + Routine symptomatic supportive treatment (34) | 1.Symptom improvement time1-1.Time to pain relief1-2.Time to blister cessation1-3.Time to scab formation1-4.Time to healing2.Total effective rate3.Adverse reactions4.Postherpetic neuralgia | 1-1.I:3.1±0.9C:5.0±1.6(P<0.01)1-2.I:4.7±1.4C:6.5±1.9(P<0.01)1-3.I:5.9±1.7C:7.8±2.1(P<0.01)1-4.I:9.8±2.1C:12.3±3.2(P<0.01)2.I:33/36(91.67)C:24/34(70.59)(P<0.05)3.I:4/36(11.11)C:2/34(5.88)(P>0.05)4.I:2/36(5.56)C:9/34(26.47)(P<0.05) | nausea,rash,abdominaldiscomfort |
| Huang 2025(1)42) | herpes zosterI:52(29/23)52.87±4.51C:52(31/21)53.60±4.29 | 4 w | LXD bid po + control (52) | Lidocaine gel + Routine treatment(antiviral therapy, immune enhancers, neurotrophic therapy (52) | 1.Total effective rate2.The immune function index levels2-1.CD3+2-2CD4+2-3.CD8+2-4.CD4+/CD8+3.Serum inflammatory factors3-1.IL-63-2.IL-103-3.TNF-α3-4.CRP4.Traditional Chinese medicine syndrome score4-1.Erosion4-2.Erythema4-3.Area of skin lesions4-4.Number of herpes4-5.Total Score5.Pain VAS6.Adverse reactions7.Postherpetic neuralgia | 1.I:50/52(96.15) C:44/52(84.62)(P<0.05)2-1.I:70.01±7.05C:58.44±7.50(P<0.05)2-2.I:50.04±5.20C:43.29±5.31(P<0.05)2-3.I:24.46±2.42C:28.51±2.40(P<0.05)2-4.I:1.95±0.74C:1.33±0.46(P<0.05)3-1.I:186.92±15.03C:241.31±14.25(P<0.01)3-2.I:177.80±15.06C:151.31±15.04(P<0.01)3-3.I:7.06±0.89C:10.02±1.78(P<0.01)3-4.I:3.28±0.57C:12.11±3.95(P<0.01)4-1.I:0.22±0.08C:0.31±0.10(P<0.01)4-2.I:0.28±0.09C:0.41±0.13(P<0.01)4-3.I:0.30±0.11C:0.45±0.15(P<0.01)4-4.I:0.24±0.09C:0.39±0.12(P<0.01)4-5.I:1.04±0.30C:1.56±0.35(P<0.01)5.I:3.29±1.07C:5.55±1.12(P<0.01)6.I:3/52(5.77)C:0/52(0)(P>0.05)7.I:1/52(1.92)C:7/52(13.46)(P<0.05) | I: dry mouth(2), increased bowel movements(1)C:none |
| Wang 201743) | herpes zosterI:50(27/23)49.5±6.7C:50(26/24)48.3±6.1 | 1 w | LXD po + control (50) | Famciclovir 0.25 g tid po (50) | 1.Symptom improvement time1-1.Time to blister cessation1-2.Time to scab formation1-3.Time to pain relief1-4.Time to healing2.Total effective rate3.Postherpetic neuralgia | 1-1.I:2.69±0.73C:3.87±0.96(P<0.05)1-2.I:6.31±1.45C:8.42±1.36(P<0.05)1-3.I:17.15±1.28C:21.42±1.17(P<0.05)1-4.I:9.02±0.74C:14.75±4.39(P<0.05)2.I:44/50(88)C:32/50(64)(P<0.05)3.I:1/50(2)C:5/50(10)(P<0.05) | NR |
| Qian 201844) | herpes zosterI:30(23/7)52.57±15.13C:30(25/5)54.1±14.56 | 1 w | LXD bid po + control (30) | Valacyclovir hydrochloride tablets 1000 ㎎ tid po + Mecobalamin tablets 500 ㎍ tid po (30) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Time to off scab2-4.Time to pain relief3.Pain VAS4.Adverse reactions5.Postherpetic neuralgia | 1.I:29/30(96.67) C:25/30(83.33)(P<0.05)2-1.I:3.23±1.07C:4.67±0.92(P<0.05)2-2.I:6.27±1.31C:8.30±1.34(P<0.05)2-3.I:11.90±2.12C:16.47±1.85(P<0.05)2-4.I:4.73±1.36C:6.80±1.35(P<0.05)3.I:1.63±1.33C:3.50±2.01(P<0.05)4.I:3/30(10)C:4/30(13.33)(P>0.05)5.I:4/30(13.33)C:14/30(46.67)(P<0.01) | I: diarrhea(3)C:diarrhea(2)drowsiness(2) |
| Wu 202445) | herpes zosterI:15(8/7)40.56±2.58C:15(9/6)41.52±2.66 | 2 w | LXD 150 ㎖ bid po + control (15) | Acyclovir 0.8 g 5 times daily po + Celecoxib 100 ㎎ bid po (15) | 1.Pain score2.White blood cell count3.Neutrophil count4.T lymphocyte count5.Symptom improvement time5-1.Time to blister cessation5-2.Time to pain relief5-3.Time to scab formation6.Traditional Chinese medicine syndrome score6-1.Number of herpes6-2.Erythema6-3.Erosion6-4.Area of skin lesions | 1.I:3.15±0.21C:4.26±0.35(P<0.05)2.I:9.25±0.23C:7.58±0.32(P<0.05)3.I:2.56±0.12C:2.01±0.13(P<0.05)4.I:736.65±22.15C:1263.98±23.17(P<0.05)5-1.I:2.15±0.65C:3.51±0.52(P<0.05)5-2.I:4.11±0.85C:6.45±0.75(P<0.05)5-3.I:5.36±0.35C:7.68±0.48(P<0.05)6-1.I:1.41±0.12C:2.15±0.21(P<0.05)6-2.I:1.15±0.24C:2.75±0.23(P<0.05)6-3.I:1.35±0.18C:1.89±0.15(P<0.05)6-4.I:1.35±0.25C:2.67±0.31(P<0.05) | NR |
| Zhou 201046) | herpes zosterI:45(20/25)52.3C:57(28/29)53.1 | 1 w | LXD 200 ㎖ tid po + control (45) | Acyclovir sustained-release tablets 0.2 g tid po + 0.1% Rivanol wet compresses(ruptured blisters) or Acyclovir ointment bid apply topically(without ruptured blisters) (57) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Time to pain relief2-4.Skin lesion healing time | 1.I:42/45(93.33) C:41/57(71.93)(P<0.01)2-1.I:2.11±0.92C:4.27±1.10(P<0.01)2-2.I:4.39±1.23C:5.99±1.36(P<0.01)2-3.I:5.01±1.58C:7.12±1.27(P<0.01)2-4.I:8.71±2.41C:11.02±2.52(P<0.01) | NR |
| Huang 2025(2)47) | herpes zosterI:60(31/29)48.39±5.25C:60(32/28)48.56±5.12 | 1 w | LXD bid po + control (60) | Acyclovir 5 ㎎/㎏ tid IV + Acyclovir ointment tid apply topically (60) | 1.Pain VAS2.Symptom improvement time2-1.Skin lesion healing time2-2.Time to scab formation2-3.Time to off scab3.Total effective rate4.Quality of life score5.Adverse reactions | 1.I:1.22±0.37C:2.13±0.29(P<0.05)2-1.I:5.47±1.42C:7.55±1.53(P<0.05)2-2.I:7.47±1.92C:9.89±1.69(P<0.05)2-3.I:11.10±1.36C:14.36±1.65(P<0.05)3.I:59/60(98.33)C:51/60(85)(P<0.05)4.I:11.19±3.02C:17.32±3.17(P<0.05)5.I:2/60(3.33)C:9/60(15)(P<0.05) | I: fatigue(1) nausea and vomiting(1)C:fatigue(2) fever(2)nausea and vomiting(3)diarrhea(2) |
| Zhang 201348) | herpes zosterI:15(8/7)58.3±3.9C:15(9/6)60.4±3.7 | 2 w | LXD + control (15) | Antiviral drugs + Neurotrophic drugs+ Vasodilators + Sedatives+ Analgesics + Acyclovir ointment (15) | 1.Total effective rate2.Pain VAS | 1.I:14/15(93.33) C:12/15(80)(P<0.05)2.I:3.14±1.38C:4.17±1.04(P<0.05) | NR |
| Wang 200949) | herpes zosterI:32(15/17)58±6.5C:32(14/18)56±6.2 | 10 d | LXD bid po + control (32) | Acyclovir tablets 0.4 g tid po + Netilmicin sulfate(those with concurrent infection) (32) | 1.Total effective rate2.Adverse reactions | 1.I:31/32(96.9) C:24/32(75)(P<0.05)2.I:0/32(0)C:0/32(0)(P>0.05) | none |
| Wang 200250) | herpes zosterI:32(20/12)48C:16(10/6)45 | 10 d | LXD po + control (32) | Valacyclovir tablets 300 ㎎ bid po (16) | 1.Total effective rate2.Onset time3.Time to significant pain relief4.Adverse reactions | 1.I:31/32(96.88) C:13/16(81.25)(P<0.01)2.I:4.2±0.8C:5.2±1.83.I:3.32±0.89C:6.68±1.174.I:1/32(3.13)C:1/16(6.25) | I: gastrointestinal symptoms(1)C:gastrointestinal symptoms(1) |
| Pei 200751) | herpes zosterW:11848 | 2 w | LXD po + control | Famciclovir tablets 250 ㎎ tid po + Topical medications(for local skin lesions) | 1.Total effective rate2.Onset time3.Adverse reactions | 1.I:53/60(88.33) C:34/58(58.62)(P<0.01)2.I:4.5C:6.53.I:19/60(31.67)C:16/58(27.59) | I: fatigue(5)dry mouth(3) dizziness and headache(5) stomach discomfort(6)C:fatigue(8) drymouth(5)dizziness and headache(3) |
| Yang 201652) | herpes zosterI:21(12/9)48.36±3.35C:21(13/8)47.46±3.27 | 1 w | LXD po + control (21) | Acyclovir injection bid IV + Acyclovir cream every two hrs 4 to 6 times a day apply topically + Vit B12 0.5 ㎎ qd IM + mecobalamin 0.5 mg tid po (21) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation3.Postherpetic neuralgia | 1.I:20/21(95.24) C:15/21(71.43)(P<0.05)2-1.I:4.36±0.16C:5.36±1.46(P<0.05)2-2.I:6.52±1.21C:7.61±1.46(P<0.05)3.I:1/21(4.76)C:6/21(28.57)(P<0.05) | NR |
| Chen 202253) | herpes zosterI:38(14/24)40.32±3.46C:38(16/22)41.23±3.34 | 2 w | LXD 200 ㎖ bid po + control (38) | Acyclovir 0.8 g 5 times daily po (38) | 1.Total effective rate2.Symptom improvement time2-1.Time to blister cessation2-2.Time to scab formation2-3.Time to pain relief2-4.Skin lesion healing time3.Traditional Chinese medicine syndrome score4.Adverse reactions5.Quality of life score5-1.Mental state5-2.Psychological function5-3.Physiological functions5-4.Bodily functions5-5.Health status5-6.Social relations | 1.I:36/38(94.74) C:30/38(78.95)(P<0.05)2-1.I:2.09±0.90C:4.28±1.12(P<0.05)2-2.I:4.36±1.22C:5.97±1.38(P<0.05)2-3.I:5.02±1.53C:7.14±1.28(P<0.05)2-4.I:8.68±2.40C:11.08±2.53(P<0.05)3.I:2.34±1.03C:3.78±1.05(P<0.05)4.I:1/38(2.63)C:7/38(18.42)(P<0.05)5-1.I:85.25±9.61C:69.35±8.45(P<0.05)5-2.I:85.32±9.56C:73.22±8.76(P<0.05)5-3.I:86.19±10.46C:75.25±8.54(P<0.05)5-4.I:85.55±7.37C:71.72±7.35(P<0.05)5-5.I:86.54±7.98C:72.61±7.33(P<0.05)5-6.I:86.56±7.15C:70.42±6.23(P<0.05) | I: headache(1)C:headache(3) fever(1)nausea(2) palpitation(1) |
| Xu 201454) | herpes zosterI:39(22/17)45.68±2.81C:39(23/16)45.82±2.91 | NR | LXD bid po + control (39) | Valacyclovir tablets 0.1 g tid po + Mecobalamin tablets 0.5 g tid po + Acyclovir eye drops five times daily + Acyclovir eye ointment once before bedtime apply topically + 1% dexamethasone-tobramycin eye drops five times daily, 1% atropine eye ointment qd(with iridocyclitis) + epidermal growth factor eye drops five times daily(with keratitis) (39) | 1.Total effective rate2.Time to healing3.Satisfaction score | 1.I:36/39(92.31) C:31/39(79.49)(P<0.05)2.I:8.94±2.98C:13.87±3.66(P<0.05)3.I:93.24±2.21C:82.17±2.56(P<0.05) | NR |